Comments to FDA: CP Requesting an Amendment of the Marketing Status for Loperamide

Herein CHPA provides comments on Citizen Petition #FDA-2016-P-43881, which requests an amendment of the marketing status for loperamide (Imodium) from nonprescription to prescription.